TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36401271

Group type: EXPERIMENTAL
Intervention: Novel disposable, self-inserted vaginal device
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group not applicable
Number of subjects: 52
Study: 36401320

Group type: EXPERIMENTAL
Intervention: Labour inspections
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guidance-through-workshops led by inspectors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 36401338

Group type: EXPERIMENTAL
Intervention: Nasal RAT
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Saliva RAT
Number of subjects: 41

Group type: COMPARATOR
Intervention: CTN swab PCR
Number of subjects: 41
Study: 36401636

Group type: EXPERIMENTAL
Intervention: Deep learning-based attenuation corrected (DLAC) polar maps
Number of subjects: 722

Group type: COMPARATOR
Intervention: Non-attenuation-corrected (NAC) polar maps
Number of subjects: 722

Group type: COMPARATOR
Intervention: Consensus of expert readers
Number of subjects: 722
Study: 36401732

Group type: EXPERIMENTAL
Intervention: GDC-0810 100-800 mg once daily or 300-400 mg twice daily
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: GDC-0810 600 mg QD taken with food
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: GDC-0810
Number of subjects: 152
Study: 36401761

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg (UPA15)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg (UPA30)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study: 36401886

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose, B12-vitamin, and folic acid administered 1 day before surgery.
Number of subjects: 442

Group type: COMPARATOR
Intervention: Control group (not screened for ID).
Number of subjects: 442
Study: 36401942

Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg intravenously every 2 weeks until hCG normalization, followed by 3 consolidation cycles
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Avelumab
Number of subjects: 7
Study: 36402009

Group type: EXPERIMENTAL
Intervention: Every additional cup of tea or coffee per day
Number of subjects: 26318

Group type: EXPERIMENTAL
Intervention: 25 g/day increment of dietary protein intake
Number of subjects: 26318
Study: 36402023

Group type: EXPERIMENTAL
Intervention: Pelvic-floor muscle training (PFMT)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Initial levels of depression
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Completion of PFMT programme
Number of subjects: 106
Study: 36402082

Group type: EXPERIMENTAL
Intervention: Prior incarceration
Number of subjects: 201
Study: 36402146

Group type: EXPERIMENTAL
Intervention: Ponatinib 30 mg orally and continuous intravenous blinatumomab 28 μg over 24 h for 28 days each cycle, followed by ponatinib monotherapy.
Number of subjects: 90
Study: 36402148

Group type: EXPERIMENTAL
Intervention: ECMO support for refractory COVID-19
Number of subjects: 1215
Study: 36402362

Group type: EXPERIMENTAL
Intervention: Barometric pressure intervention, specific details not provided.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, specific details not provided.
Number of subjects: 0
Study: 36402456

Group type: EXPERIMENTAL
Intervention: Cryopreserved bone marrow from deceased organ donors (VB-derived HPCs)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Bone marrow aspirated from living donors (iliac crest)
Number of subjects: 250
Study: 36402744

Group type: EXPERIMENTAL
Intervention: Novel radiation therapy schedule (3.96 Gy × 7 followed by 1.0 Gy × 9)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Novel radiation therapy schedule
Number of subjects: 14
Study: 36402752

Group type: EXPERIMENTAL
Intervention: PD-L1-targeting chimeric switch receptor (PD-L1.BB CSR) modified CAR-T cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional 2nd-generation CAR-T cells
Number of subjects: 0
Study: 36402958

Group type: EXPERIMENTAL
Intervention: Clinical staff measuring VA function (Assessor 1)
Number of subjects: 612

Group type: COMPARATOR
Intervention: Reference standard (Assessor 2)
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Feasibility questionnaires and semi-structured interviews
Number of subjects: 612
Study: 36402970

Group type: EXPERIMENTAL
Intervention: Microvascular decompression (MVD)
Number of subjects: 115
Study: 36403022

Group type: EXPERIMENTAL
Intervention: Non-CF bronchiectasis patients (BE group)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Healthy volunteers (HC group)
Number of subjects: 61
Study: 36403075

Group type: EXPERIMENTAL
Intervention: Harm reduction (HR) organization services
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mental health and financial wellbeing
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Drug quality
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Trust in healthcare providers
Number of subjects: 20
Study: 36403579

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (1.8 mg/kg) plus nivolumab (3 mg/kg) intravenously starting 30-60 days after autologous HSCT for up to 8 cycles.
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin plus nivolumab
Number of subjects: 59
Study: 36403700

Group type: EXPERIMENTAL
Intervention: Bivalent SARS-CoV-2 recombinant protein vaccine, SCTV01C
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36403862

Group type: EXPERIMENTAL
Intervention: Premenopausal risk-reducing salpingo-oophorectomy
Number of subjects: 368

Group type: COMPARATOR
Intervention: Postmenopausal risk-reducing salpingo-oophorectomy
Number of subjects: 368
Study: 36403926

Group type: EXPERIMENTAL
Intervention: Presence of hyperreflective foci (HRF)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Subretinal drusenoid deposits (SDD) only
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Presence of hyperreflective foci (HRF) and SDD
Number of subjects: 158
Study: 36404213

Group type: EXPERIMENTAL
Intervention: Biphasic pulses with interphase gap of 0 μs
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Biphasic pulses with interphase gaps of 10, 20, 50, and 100 μs
Number of subjects: 9
Study: 36404274

Group type: EXPERIMENTAL
Intervention: PDAC-DM
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: CP-DM
Number of subjects: 165

Group type: COMPARATOR
Intervention: T2DM
Number of subjects: 165
Study: 36404384

Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Number of subjects: 9
Study: 36404403

Group type: EXPERIMENTAL
Intervention: Saliva-based SARS-CoV-2 screening testing
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 screening testing
Number of subjects: 31
Study: 36404469

Group type: EXPERIMENTAL
Intervention: Vitamin D treatment, specific dosage and duration not mentioned
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 36404528

Group type: EXPERIMENTAL
Intervention: HBO prior to SRS
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control
Number of subjects: 38
Study: 36404708

Group type: EXPERIMENTAL
Intervention: Factor D (FD) inhibitor, danicopan
Number of subjects: 29
Study: 36404730

Group type: EXPERIMENTAL
Intervention: Lifestyle program; details on dosage and duration not available
Number of subjects: 0
Study: 36405821

Group type: EXPERIMENTAL
Intervention: 8 weeks of corticosteroid therapy (Group A)
Number of subjects: 33

Group type: COMPARATOR
Intervention: 12-14 weeks of standard therapy (Group B)
Number of subjects: 33
Study: 36405923

Group type: EXPERIMENTAL
Intervention: MDMA-assisted therapy (MDMA-AT)
Number of subjects: 32
Study: 36406365

Group type: EXPERIMENTAL
Intervention: High serum NLRP3 protein level at the end of the operation
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Cognitive dysfunction
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: NLRP3 protein levels
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: PND incidence
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: High serum NLRP3 protein level, old age
Number of subjects: 75
Study: 36406817

Group type: EXPERIMENTAL
Intervention: Oral ferrous sulfate 325 mg twice daily for 12 months
Number of subjects: 16
Study: 36407071

Group type: EXPERIMENTAL
Intervention: Polyvascular disease
Number of subjects: 8856

Group type: COMPARATOR
Intervention: CAD only
Number of subjects: 8856
Study: 36407294

Group type: EXPERIMENTAL
Intervention: TMD diagnosis and assessment through validated questionnaires
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Screening for psychosocial status
Number of subjects: 219
Study: 36407519

Group type: EXPERIMENTAL
Intervention: Pre-/post-nutrient timing
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control
Number of subjects: 64
Study: 36407523

Group type: EXPERIMENTAL
Intervention: Maternal adiposity (measured by BMI)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Maternal adiposity (overweight mothers)
Number of subjects: 223
Study: 36407522

Group type: EXPERIMENTAL
Intervention: 7-day fast followed by an 11-week plant-based diet (PBD)
Number of subjects: 53

Group type: COMPARATOR
Intervention: 12-week standard DGE diet
Number of subjects: 53
Study: 36408119

Group type: EXPERIMENTAL
Intervention: Mindful Moment intervention
Number of subjects: 292
Study: 36408118

Group type: EXPERIMENTAL
Intervention: Brief mindfulness-based intervention (MBI) named 'STOP touching your face'
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (wait-list)
Number of subjects: 0
Study: 36408511

Group type: EXPERIMENTAL
Intervention: Prediction model based on clinical data from the DIRECT-MT trial
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: ICAS-LVO group (45 cases)
Number of subjects: 656

Group type: COMPARATOR
Intervention: Non-ICAS-LVO group (611 cases)
Number of subjects: 656
Study: 36408587

Group type: EXPERIMENTAL
Intervention: Berotralstat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 36408618

Group type: EXPERIMENTAL
Intervention: 1×MVA
Number of subjects: 745

Group type: EXPERIMENTAL
Intervention: 2×MVA
Number of subjects: 745

Group type: EXPERIMENTAL
Intervention: HSPX
Number of subjects: 745

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 745
Study: 36408866

Group type: EXPERIMENTAL
Intervention: Pulmonary function test (PFT)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Trunk Impairment Scale (TIS)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Barthel Index (BI)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Respiratory muscle strength
Number of subjects: 25
Study: 36408876

Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrate (PCC)
Number of subjects: 4993
Study: 36408923

Group type: EXPERIMENTAL
Intervention: Thermal ablation treatment
Number of subjects: 2019
Study: 36409100

Group type: EXPERIMENTAL
Intervention: Mindful Emotion Awareness + Cognitive Reappraisal (MEA + CR)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Mindful Emotion Awareness (MEA)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Cognitive Reappraisal (CR)
Number of subjects: 234
Study: 36409226

Group type: EXPERIMENTAL
Intervention: Work-related group cognitive behavioral therapy plus vocational services (WCBT+VSAU)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Vocational services only (VSAU-alone)
Number of subjects: 250
Study: 36409282

Group type: EXPERIMENTAL
Intervention: Low-dose extended half-life (EHL) FVIII prophylaxis with PK-based adjustment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Low-dose standard half-life (SHL) FVIII prophylaxis
Number of subjects: 15
Study: 36409354

Group type: EXPERIMENTAL
Intervention: Maximal tolerable doses of evidence-based medications
Number of subjects: 224
Study: 36409541

Group type: EXPERIMENTAL
Intervention: PlusCare digital app for HIV case management
Number of subjects: 45
Study: 36409543

Group type: EXPERIMENTAL
Intervention: Human Milk Composition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infant Growth
Number of subjects: 0
Study: 36409612

Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 59
Study: 36409676

Group type: EXPERIMENTAL
Intervention: Social Work Intervention for Palliative Care
Number of subjects: 0
Study: 36409740

Group type: EXPERIMENTAL
Intervention: HIV+ men
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: HIV+ women
Number of subjects: 481

Group type: COMPARATOR
Intervention: HIV- participants
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: PWH
Number of subjects: 481
Study: 36409773

Group type: EXPERIMENTAL
Intervention: Therapeutic responses to available and new compounds against Trypanosoma cruzi infection.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quantitative-PCR data obtained from blood samples collected regularly over a year.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Categorization of individuals based on distinct parasitological status.
Number of subjects: 0
Study: 36409927

Group type: EXPERIMENTAL
Intervention: Follicular flushing during oocyte retrieval
Number of subjects: 1643

Group type: COMPARATOR
Intervention: Aspiration alone
Number of subjects: 1643
Study: 36409958

Group type: EXPERIMENTAL
Intervention: EASE mobile app intervention
Number of subjects: 800

Group type: COMPARATOR
Intervention: Active comparison control app
Number of subjects: 800
Study: 36410013

Group type: EXPERIMENTAL
Intervention: Neuroimaging measures including multimodal Magnetic Resonance Imaging (MRI) and Spectroscopy (MRS) scans of the brain and spinal cord, clinical, cognitive, mood and speech assessments, blood sample collection.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (104 participants) matched for age, sex, handedness, and years of education.
Number of subjects: 200
Study: 36410034

Group type: EXPERIMENTAL
Intervention: Triple antithrombotic therapy (TAT)
Number of subjects: 647

Group type: COMPARATOR
Intervention: Dual antithrombotic therapy (DAT)
Number of subjects: 647
Study: 36410152

Group type: EXPERIMENTAL
Intervention: MDZ-NS 5 mg administered for seizure clusters, with a second dose possible within 10 minutes if seizures did not terminate or recurred within 6 hours.
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: MDZ-NS
Number of subjects: 175
Study: 36410207

Group type: EXPERIMENTAL
Intervention: Intravenous pertuzumab plus trastuzumab (PH IV)
Number of subjects: 4772

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC)
Number of subjects: 4772
Study: 36410339

Group type: EXPERIMENTAL
Intervention: WL + EX
Number of subjects: 44

Group type: COMPARATOR
Intervention: WL
Number of subjects: 44
Study: 36410441

Group type: EXPERIMENTAL
Intervention: Balloon-expandable SAPIEN-3 Ultra
Number of subjects: 440

Group type: COMPARATOR
Intervention: Self-expanding EVOLUT PRO+
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 440
Study: 36410605

Group type: EXPERIMENTAL
Intervention: Anteroposterior (AP) pacer pad position
Number of subjects: 20

Group type: COMPARATOR
Intervention: Anterolateral (AL) pacer pad position
Number of subjects: 20
Study: 36410797

Group type: EXPERIMENTAL
Intervention: Heart rate variability biofeedback (HRV-B) intervention using a Polar chest strap device linked to the Elite HRV phone application for 4 weeks, with two 10-minute sessions daily for at least 5 days a week.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Heart rate variability biofeedback (HRV-B) intervention
Number of subjects: 30
Study: 36410805

Group type: EXPERIMENTAL
Intervention: Experimental menthol VLNCs
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Experimental non-menthol VLNCs
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Proposed product standards
Number of subjects: 172
Study: 36410804

Group type: EXPERIMENTAL
Intervention: Resistell AST
Number of subjects: 300
Study: 36410808

Group type: EXPERIMENTAL
Intervention: Annual follow-up by GP with clinical and laboratory data collection and lifestyle questionnaires at inclusion, 2-year, and 5-year follow-ups.
Number of subjects: 0
Study: 36410913

Group type: EXPERIMENTAL
Intervention: Investigator-Initiated Trials (IITs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 36411033

Group type: EXPERIMENTAL
Intervention: Gepotidacin 3000 mg oral doses administered 10-12 hours apart
Number of subjects: 0
Study: 36411081

Group type: EXPERIMENTAL
Intervention: Cladribine tablets
Number of subjects: 57
Study: 36411150

Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS)
Number of subjects: 89
Study: 36411203

Group type: EXPERIMENTAL
Intervention: Saliva-based miRNA signature for endometriosis-associated infertility
Number of subjects: 200

Group type: COMPARATOR
Intervention: Saliva samples from patients diagnosed with endometriosis
Number of subjects: 200
Study: 36411217

Group type: EXPERIMENTAL
Intervention: High dairy (HD) diet (4 servings/day for six weeks)
Number of subjects: 10
Study: 36411267

Group type: EXPERIMENTAL
Intervention: AZD7442 (tixagevimab/cilgavimab) 300 mg (1.5 mL intramuscular injection)
Number of subjects: 1121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1121
Study: 36411966

Group type: EXPERIMENTAL
Intervention: Fetal Growth Restriction (FGR) fetuses
Number of subjects: 36

Group type: COMPARATOR
Intervention: Healthy fetuses with birthweights between the 10th and the 90th percentile (average for gestational age [AGA])
Number of subjects: 36
Study: 36412064

Group type: EXPERIMENTAL
Intervention: Pembrolizumab and vorinostat
Number of subjects: 50
Study: 36412069

Group type: EXPERIMENTAL
Intervention: Frontline worker (FLW) visits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FLW visits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Satisfaction with FLW visits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Development index
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Percentage of scheduled caste or tribe
Number of subjects: 0
Study: 36412095

Group type: EXPERIMENTAL
Intervention: peg-interferon beta-1a
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 36412229

Group type: EXPERIMENTAL
Intervention: Man Therapy (MT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 36412278

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 screening testing program in Durham schools
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 screening testing program in Kansas City schools
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Community positivity rates
Number of subjects: 1600
Study: 36412504

Group type: EXPERIMENTAL
Intervention: MULTI_sh (multidisciplinary lifestyle intervention)
Number of subjects: 74
Study: 36412692

Group type: EXPERIMENTAL
Intervention: Cellular Bone Allograft (CBA)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: CBA
Number of subjects: 201
Study: 36412798

Group type: EXPERIMENTAL
Intervention: Midline Catheters
Number of subjects: 44

Group type: COMPARATOR
Intervention: Peripheral Intravenous Catheters (PIVC)
Number of subjects: 44
Study: 36413013

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36413080

Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg
Number of subjects: 1531

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1531

Group type: COMPARATOR
Intervention: Adalimumab 40 mg
Number of subjects: 1531

Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg in open-label extensions (OLEs)
Number of subjects: 1531
Study: 36413141

Group type: EXPERIMENTAL
Intervention: Combined onvansertib and abiraterone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Abiraterone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plk1 inhibition (onvansertib)
Number of subjects: 0
Study: 36413205

Group type: EXPERIMENTAL
Intervention: Physical activity meeting current recommendations
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Sleep duration meeting current recommendations
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Weekly physical activity levels
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Sleep duration
Number of subjects: 445
Study: 36413221

Group type: EXPERIMENTAL
Intervention: Blended care (interactive e-learning program based on cognitive behavioral therapy for insomnia)
Number of subjects: 916

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 916
Study: 36413389

Group type: EXPERIMENTAL
Intervention: Smart continence care (SCC) for 3 months
Number of subjects: 160

Group type: COMPARATOR
Intervention: Regular continence care (RCC)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Smart continence care (SCC)
Number of subjects: 160
Study: 36413390

Group type: EXPERIMENTAL
Intervention: App-based cognitive behavioral therapy (CBT) delivered via a mobile health (mHealth) app for 12 weeks.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Wait list control condition.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: App-based cognitive behavioral therapy (CBT) delivered via a mobile health (mHealth) app.
Number of subjects: 18
Study: 36413408

Group type: EXPERIMENTAL
Intervention: Metabolically compromised and older individuals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Young and older trained individuals
Number of subjects: 0
Study: 36413418

Group type: EXPERIMENTAL
Intervention: Tralesinidase alfa (300 mg)
Number of subjects: 22
Study: 36413425

Group type: COMPARATOR
Intervention: Higher-dose heparin
Number of subjects: 1045

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 1045

Group type: COMPARATOR
Intervention: Heparin started 12 hours before surgery
Number of subjects: 1045

Group type: COMPARATOR
Intervention: Combined mechanical and pharmacological prophylaxis (enoxaparin)
Number of subjects: 1045
Study: 36413436

Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering treatment or statins
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36413586

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 18244

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 18244
Study: 36414239

Group type: EXPERIMENTAL
Intervention: Cryoballoon-based pulmonary vein isolation (PVI) with phrenic nerve injury (PNI)
Number of subjects: 111
Study: 36414294

Group type: EXPERIMENTAL
Intervention: Vocal biomarker derived from AI-based algorithm
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Machine learning algorithms (logistic regression, k-nearest neighbours, support vector machine, soft voting classifier)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Vocal biomarker
Number of subjects: 296